Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Northwest Biotherapeutics (NWBO) over the last 16 years, with Q3 2025 value amounting to $1.3 million.

  • Northwest Biotherapeutics' Change in Accured Expenses fell 6044.91% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 56027.1%. This contributed to the annual value of $8.9 million for FY2024, which is 29966.49% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Change in Accured Expenses stood at $1.3 million for Q3 2025, which was down 6044.91% from $3.2 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Change in Accured Expenses' 5-year high stood at $5.0 million during Q3 2021, with a 5-year trough of -$7.1 million in Q4 2023.
  • For the 5-year period, Northwest Biotherapeutics' Change in Accured Expenses averaged around $849157.9, with its median value being $975000.0 (2023).
  • In the last 5 years, Northwest Biotherapeutics' Change in Accured Expenses plummeted by 62256.41% in 2023 and then skyrocketed by 64057.65% in 2024.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Change in Accured Expenses stood at -$3.0 million in 2021, then skyrocketed by 145.12% to $1.4 million in 2022, then tumbled by 622.56% to -$7.1 million in 2023, then skyrocketed by 105.64% to $402000.0 in 2024, then surged by 228.61% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $3.2 million for Q2 2025, and $4.4 million during Q1 2025.